Cytokinetics Announces Changes to Its Board of Directors
(Thomson Reuters ONE) -
Steve Dow Will Not Stand for Re-Election at the Annual Meeting of Shareholders;
B. Lynne Parshall Has Been Appointed to the Company's Board
South San Francisco, CA, February 8, 2013 - Cytokinetics, Incorporated (Nasdaq:
CYTK) announced today that Steve Dow has provided notification that he will not
stand for re-election to the Company's Board of Directors at its Annual Meeting
of Shareholders to occur on May 22, 2013. Mr. Dow has indicated he will
continue his service to the Cytokinetics' Board until the expiration of his
current term. Contemporaneously with Mr. Dow's notice, the Board has appointed
Ms. B. Lynne Parshall, Esq. to the company's Board, effective February 7, 2013.
"We would like to thank Steve for his longstanding and dedicated service to the
company," stated Robert I. Blum, Cytokinetics' President and Chief Executive
Officer. "Steve has served on our Board since the company's founding and we are
fortunate to have had the benefit of his expertise and wise counsel. On behalf
of Cytokinetics' management and our Board, we are grateful for his strategic
insights and professional oversight that have contributed to the company's
successes."
B. Lynne Parshall joins the Cytokinetics Board of Directors with over 21 years
of legal, financial, manufacturing, general management and corporate development
experience in the biopharmaceutical industry. Ms. Parshall is currently a
member of the Board of Directors and the Chief Operating Officer of Isis
Pharmaceuticals, Inc., a public biopharmaceutical company focused on antisense
drug discovery and development. Prior to joining Isis Pharmaceuticals, Ms.
Parshall was a partner with the firm of Cooley Godward LLP, where she
represented health care companies in a general practice specializing in
corporate partnering and other technology-based transactions. Ms. Parshall
currently serves on the Board of Regulus Therapeutics Inc., a public
biopharmaceutical company co-founded by Isis. Ms. Parshall is a member of the
American, California and San Diego bar associations. Ms. Parshall received her
J.D. from Stanford Law School and her B.A. from Harvard University.
"We are pleased to welcome Lynne to the Cytokinetics Board. Her extensive
operational and business development experience, particularly in the advancement
and funding of potential products directed to specialty care and orphan drug
designated indications, will be valuable to our company as we may advance our
own drug candidates in late-stage clinical trials." continued Mr. Blum. "Lynne
has successfully led the strategic direction and growth of Isis Pharmaceuticals
over the last 20 years. We look forward to having the benefit of her
biopharmaceutical operating experience to assist our financial and business
development strategies and company planning."
About Cytokinetics
Cytokinetics is a clinical-stage biopharmaceutical company focused on the
discovery and development of novel small molecule therapeutics that modulate
muscle function for the potential treatment of serious diseases and medical
conditions. Cytokinetics' lead drug candidate from its cardiac muscle
contractility program, omecamtiv mecarbil, is in Phase II clinical development
for the potential treatment of heart failure. Amgen Inc. holds an exclusive
license worldwide (excluding Japan) to develop and commercialize omecamtiv
mecarbil and related compounds, subject to Cytokinetics' specified development
and commercialization participation rights. Cytokinetics is independently
developing tirasemtiv, a skeletal muscle activator, as a potential treatment for
diseases and conditions associated with aging, muscle wasting or neuromuscular
dysfunction. Tirasemtiv is currently the subject of a Phase II clinical trials
program and has been granted orphan drug designation and fast track status by
the U.S. Food and Drug Administration and orphan medicinal product designation
by the European Medicines Agency for the potential treatment of amyotrophic
lateral sclerosis, a debilitating disease of neuromuscular impairment in which
treatment with tirasemtiv produced potentially clinically relevant
pharmacodynamic effects in Phase II trials. All of these drug candidates have
arisen from Cytokinetics' muscle biology focused research activities and are
directed towards the cytoskeleton. The cytoskeleton is a complex biological
infrastructure that plays a fundamental role within every human cell. Additional
information about Cytokinetics can be obtained at www.cytokinetics.com.
This press release contains forward-looking statements for purposes of the
Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics
disclaims any intent or obligation to update these forward-looking statements,
and claims the protection of the Act's safe harbor for forward-looking
statements. Examples of such statements include, but are not limited to,
statements relating to the properties and potential benefits of Cytokinetics'
drug candidates and the potential advancement of its drug candidates in late-
stage clinical trials. Such statements are based on management's current
expectations, but actual results may differ materially due to various risks and
uncertainties, including, but not limited to, potential difficulties or delays
in the development, testing, regulatory approval and production of Cytokinetics'
drug candidates and potential drug candidates that could slow or prevent
clinical development or product approval, including risks that current and past
results of clinical trials or preclinical studies may not be indicative of
future clinical trials results and that Cytokinetics' drug candidates and
potential drug candidates may have unexpected adverse side effects or inadequate
therapeutic efficacy. For further information regarding these and other risks
related to Cytokinetics' business, investors should consult Cytokinetics'
filings with the Securities and Exchange Commission.
Contact:
Joanna (Jodi) L. Goldstein
Manager, Marketing & Corporate Communications
(650) 624-3000
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Cytokinetics, Inc. via Thomson Reuters ONE
[HUG#1676604]
Unternehmensinformation / Kurzprofil:
Datum: 08.02.2013 - 13:30 Uhr
Sprache: Deutsch
News-ID 227734
Anzahl Zeichen: 7486
contact information:
Town:
SOUTH SAN FRANCISCO
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 187 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Cytokinetics Announces Changes to Its Board of Directors"
steht unter der journalistisch-redaktionellen Verantwortung von
Cytokinetics, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
